Tests VV-14303 gene therapy for fatty liver disease called MASH
Tests a gene therapy, VV-14303, in adults with MASH fatty liver disease.
Key facts
- Who runs it
- Kriya Therapeutics, Inc.
- Where
- Auckland, New ZealandSee the siteAlso in 1 other country, 2 sites
- Trial code
- Registry title
- A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 56 people, planned
- Started
- 30 Jul 2026
- Expected to end
- Jul 2029
- Type of study
- Interventional, 4 groups
- Treatments tested
- VV-14303
- Record updated
- 1 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with MASH confirmed by a liver biopsy and metabolic risk factors. It tests a gene therapy called VV-14303.
- Age
- 18 to 75 years
- Sex
- All sexes. Men must use highly effective contraception. Women cannot be able to have children.
- Disease stage
- MASH confirmed by liver biopsy. At least 2 metabolic risk factors: obesity, high blood pressure, abnormal blood fats or type 2 diabetes. BMI of 25 to under 40 kg/m2.
- Earlier treatment
- Medicines for diabetes or metabolic syndrome, and Resmetirom, must have been stable for at least 6 months before screening. No earlier AAV or adenoviral therapy or gene therapy trial.
Main reasons for not taking part
- Another or additional liver disease, such as chronic viral hepatitis or autoimmune hepatitis
- Type 1 diabetes, or poorly controlled type 2 diabetes (HbA1c above 8.0% (64 mmol/mol))
- Earlier AAV or adenoviral therapy, or any earlier gene therapy trial
- Other systemic experimental treatment within 6 weeks or 5 half-lives
- Any vaccination within 30 days before dosing, or planned within 8 weeks after dosing
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Participant is capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
- Must be 18 to 75 years of age (inclusive) at Screening
- Body Mass Index (BMI) of 25 to <40 kg/m2 (inclusive)
- Male participants must agree to use a highly effective contraception during the Treatment Period and at least 12 months after administration of VV-14303. Female participants must not be a woman of child-bearing potential (WOCBP)
- Biopsy-confirmed MASH
- Previous history or presence of ≥2 of the following metabolic risk factors: obesity (BMI ≥25 kg/m²), hypertension (blood pressure [BP] ≥140/90 mmHg or on antihypertensive medication), dyslipidemia (triglycerides ≥150 mg/dL or high-density lipoprotein cholesterol [HDL-C] <40 mg/dL in men/<50 mg/dL in women or on lipid-lowering therapy), type 2 diabetes mellitus
- Must be willing to refrain from the donation of blood, plasma, platelets, eggs, or sperm during the 12-month post-treatment follow-up period
Who cannot take part
- Use of Resmetirom that has not been stable for at least 6 months prior to Screening visit
- Any medical, cognitive, or psychiatric condition that, in the opinion of the Investigator, could contraindicate the use of the investigational drug, make consistent study assessment and follow-up over the 12-month Post-Treatment Follow-up Period unlikely, or would make the participant an unsafe study candidate
- History of major trauma to the muscle(s) intended for IM injection meeting any of the following criteria:; Within 6 months prior to Screening, or; At any timepoint prior to Screening with continued neurologic or musculoskeletal symptoms
- Prior participation in any systemic experimental treatment or receiving any other systemic investigational treatment including within 6 weeks or 5 half-lives of the active ingredient (whichever is longer) prior to the start of Screening
- Any vaccination or planned vaccination 30 days prior to dosing, or planned vaccination 8 weeks post dosing
- Previously received AAV or adenoviral therapy or participation in any previous gene therapy trial
- Presence of alternate and/or additional liver disease etiologies at Screening, including but not limited to chronic viral hepatitis, autoimmune hepatitis
- Use of treatments for metabolic syndrome management, including oral antidiabetic drugs (OADs) (e.g., metformin), incretin mimetics (GLP-1 receptor agonists or GLP-1/gastric inhibitory polypeptide [GIP] agonists) or other glucose-lowering agents that has not been stable for at least 6 months prior to Screening
- Type 1 diabetes, or poorly controlled type 2 diabetes (HbA1c > 8.0% at Screening)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in New Zealand
Also in 1 other country, 2 sites
- AucklandHospital not named in the registryContact: VP, Medical AffairsNot yet recruiting
About the trial
What the trial wants to find out
A Study of VV-14303 for the Treatment of Metabolic dysfunction-associated steatohepatitis (MASH)
The 4 groups in the trial
- Part 1 Cohort 1, dose #1Treatment being tested
Dose #1 of VV-14303 will be administered
Treatment: VV-14303
- Part 1 Cohort 2, dose #2Treatment being tested
Dose #2 of VV-14303 will be administered
Treatment: VV-14303
- Part 1 Cohort 3, dose #3Treatment being tested
Dose #3 of VV-14303 will be administered
Treatment: VV-14303
- Part 2 doseTreatment being tested
VV-14303 will be administered at the dose determined from Part 1 (Cohorts 1, 2, and 3)
Treatment: VV-14303
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1/2, First-in-Human, Multi-Arm, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Efficacy of VV-14303, an Adeno-associated Virus Vector-mediated Fibroblast Growth Factor 21 (FGF21) Gene Therapy, in Adults With Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Plain-language title
- Tests VV-14303 gene therapy for fatty liver disease called MASHGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07732400, who can take part
- Record updated
- 1 September 2026